AngioDynamics, Inc. (ANGO) FinancialsANGOFinancialAngioDynamics, Inc.

AngioDynamics, Inc. (ANGO) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Med Device, accounting for 51.8% of total sales, equivalent to $44.85M. Another important revenue stream is Med Tech. Understanding this composition is critical for investors evaluating how ANGO navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, AngioDynamics, Inc. maintains a gross margin of 50.87%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -6.36%, while the net margin is -13.17%. These profitability ratios, combined with a Return on Equity (ROE) of -20.77%, provide a clear picture of how effectively ANGO converts its operational activities into shareholder value.

In the context of the broader market, ANGO competes directly with industry leaders such as MDXG and KIDS. With a market capitalization of $655.12M, it holds a leading position in the sector. When comparing efficiency, ANGO's gross margin of 50.87% stands against MDXG's 68.50% and KIDS's 74.27%. Such benchmarking helps identify whether AngioDynamics, Inc. is trading at a premium or discount relative to its financial performance.

AngioDynamics has shown consistent revenue growth, with Q4 2026 revenue reaching $86.6 million, an 8% increase from the previous year. The gross margin is stable at around 50%, indicating solid profitability despite recent losses.